Author: Michelle Sommer
Why do certain congenital kidney disorders vary so widely in severity among affected individuals? Can AI improve breast cancer diagnostics? These are the questions being addressed in current projects by two early-career researchers at the Heidelberg Faculty of Medicine at Heidelberg University. The Else Kröner-Fresenius Stiftung is supporting the research of Dr. Caroline M. Kolvenbach […]
read more
QuantiLight licences Max Planck sensor technology
Exclusive global licence forms the basis for a portable system for the rapid determination of drug levels following organ transplants November 03, 2026 To the Point Transplant recipients require regular blood tests to ensure that the concentration of anti-rejection drugs remains within an appropriate range. Too low a drug concentration can increase the risk of […]
read more
Lost in the Crowd? How Crowding Affects Drug-Protein Binding
2. November 2026 Macromolecular crowding, such as in the interior of biological cells, profoundly influences how molecules interact; however, its effects on drug-target binding rates and pathways remain poorly understood. In a recent publication, researchers from the Molecular and Cellular Modelling (MCM) group have developed a novel multiresolution Brownian dynamics framework to tackle the complexity […]
read more
Understanding the rules of brain cancer
AI and single-cell omics technologies are helping us uncover the rules that determine how cells in glioblastoma – a type of incurable brain cancer – acquire different fates, enabling researchers to experimentally change them Summary Glioblastoma is the deadliest and most common type of malignant brain tumour in adults. One of the reasons it’s almost […]
read more
Watching ribosomes in the making all at once
Scientists used 3D images of the human nucleolus to visualise ribosome assembly pathways inside cells for the first time Summary For decades, ribosomes have been, quite literally, under the lens of many scientists. Ribosomes are highly sophisticated and complex molecular machines that allow cells to synthesise proteins. However, putting ribosomes together requires intricate assembly processes. […]
read more
Hummingbird Diagnostics Showcases New Data Utilizing Blood-Based Small RNA for Lung Cancer Treatment Monitoring at ESMO Congress 2026
Study demonstrates the ability of small RNA to inform lung cancer treatment strategies HEIDELBERG, Germany, October 26, 2026 – Hummingbird Diagnostics GmbH, a pioneer in blood-based small RNA biomarker discovery and assay development, today announced new clinical data demonstrating the ability of small RNA to enable adaptive treatment strategies in lung cancer patients. The results […]
read more
Newsletter der BMBH: Biobanking Update!
Informationen über unsere Aktivitäten und aktuelle Entwicklungen im Biobanking am Standort und darüber hinaus. IN DIESER AUSGABE__Die BMBH im ÜberblickAktuelles aus der BMBHAktuelles aus denMitgliedsbiobankenNationale / InternationaleBiobanking-AktivitätenPublikationenAnstehende Termine
read more
Huntington’s Disease Biomarkers: Key Molecular Targets and Antibody Tools for HD Research
Proteins to Watch in Huntington’s Disease Research When developing assays to study Huntington’s disease (HD), scientists have a rare advantage: they know the exact genetic cause. But that hasn’t made the biological mechanism any easier to tackle. Despite decades of research, effective treatments remain limited for this progressive degenerative disease.2 HD is inherited in an autosomal-dominant […]
read more
Highly Sensitive Detection of MRI Contrast Agents
Gadolinium is a component of contrast agents used in MRI examinations, which can be released into the environment through patients’ urine. Scientists at the German Cancer Research Center (DKFZ) have now developed a sensor capable of detecting even the smallest amounts of gadolinium. Magnetic resonance imaging, or MRI for short, provides detailed images of the […]
read more
